Enter your contact details & our Business Development
expert will circle back to address your request!
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting the cholangiocarcinoma market. In addition to it, rising exposure to harmful chemicals for printing and other process is escalating the market. On the other hand, time-consuming method towards the diagnosis and treatment, high cost and numerous processes for diagnosis and treatment of cancer can be a restraint in the growth of this market.
The rising research and development actions by pharmaceutical companies. For instance, in January 2020, Sirnaomics Inc. and Innovent Biologics, Inc. announced the collaboration for research and development using Sirnaomics’ RNAi drug candidate STP705 (cotsiranib) and Innovent’s antibody drug Tyvyt (sintilimab injection), as a combination treatment in advanced cancers such as Hepatocellular Carcinomas (HCC) and Cholangiocarcinoma (CCA). Therefore, increasing number of lead candidates in late phase clinical trial having the potential to gain regulatory approval in providing a robust opportunity for pharmaceutical manufacturers to launch novel drugs for the treatment of cholangiocarcinoma.
COVID 19 has affected many occupational sectors, and the budget of several regions deteriorated owing to the effect. Pandemic affected the economy by straight affecting the manufacturing and demand, disturbing the supply channel and having a severe financial impact on the global market. During the pandemic in June 2020, the national health institute broadcasted COVID 19 research initiatives through antibody testing. Constant growing population for cancer diagnosis through the period with have a helpful impact on the market. As the request for medical equipment augmented and people visited hospitals more than before throughout the novel coronavirus spread, the market positively impacted the virus spread.
The categories of treatment are chemotherapy and radiotherapy. The cholangiocarcinoma market Size is fragmented into 5-fluorouracil, gemcitabine, cisplatin, and others based on the sub-segment chemotherapy.
Distribution Channel Insights
On the basis of distribution channel, the cholangiocarcinoma market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of cholangiocarcinoma during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of patients globally are the major aspects for the growth of the segment.
North America is governing the market, and it is anticipated that it will remain to dominate in the forecasted period. The factors the region embraces the major growth are the well-developed healthcare sector, growing number of cancer patients, and accumulating government expenditure on healthcare. In 2015, healthcare expenditure in the U.S. touched $3.2 trillion per person, 17.8% of the total GDP. The accessibility of funds for research, intensifying patient population and government support for the research and development of medication in Europe and Asia pushes the market towards growth.
Europe holds the second-largest cholangiocarcinoma market share. Owing to the continuous growth in the region like India and China, the market is experiencing high opportunities in the future. In India, the healthcare spending accounted for the fastest CAGR.
Key Companies Insights
The market for cholangiocarcinoma is moderately competitive. With the rising applications of Cholangiocarcinoma, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Cholangiocarcinoma market, ultimately boosting the market growth. Some of the key companies working in the global Cholangiocarcinoma market include:
• Johnson & Johnson Private Limited
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc
• AbbVie Inc.
• Novartis AG
• Fresenius Kabi AG
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Intercept Pharmaceuticals
• Kyowa Kirin Co., Ltd.
• Delcath Systems, Inc.
• Accord Healthcare
• CONMED Corporation
• Boston Scientific Corporation
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Other players
Some of the Recent Developments:
• In April 2020, the U.S. Food and Drug Administration had permitted the first targeted therapy for patients with cholangiocarcinoma called Pemazyre (pemigatinib). Pemazyre's sanction was founded on the outcomes of a clinical trial in which 107 patients with locally progressive or metastatic cholangiocarcinoma who had earlier received therapy and had a FGFR2 fusion or rearrangement were joined.
• In September 2019, Merck Sharp & Dohme Corp initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment bile duct cancer. The study is now in Phase 3 clinical trials and is anticipated to be completed by August 2023.
By Treatment Type
o 5 fluorouracil (5-FU)
• Targeted Therapy
o Infigratinib (Phase 3)
o Ivosidenib (Phase 3)
o Pembrolizumab (Phase 3)
By Disease Indication
• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• North America
o South Korea
• Latin America
o South Africa
o Saudi Arabia
Please fill form below:
99 WALL STREET #2124 NEW YORK, NY 10005